Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
about
Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart AssociationTherapeutic advances in the treatment of vasculitisUse of corticosteroids during acute phase of Kawasaki diseaseKawasaki Disease: A Clinician's UpdateOxidative stress and Kawasaki disease: how is oxidative stress involved from the acute stage to the chronic stage?Heart disease and stroke statistics--2014 update: a report from the American Heart AssociationHeart Disease and Stroke Statistics-2017 Update: A Report From the American Heart AssociationIs dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeA comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki diseaseRisk factors and implications of progressive coronary dilatation in children with Kawasaki diseaseA multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin GImmunoglobulin Resistance in Kawasaki Disease.Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics.The Complexities of the Diagnosis and Management of Kawasaki Disease.Development of coronary artery lesions in indolent Kawasaki disease following initial spontaneous defervescence: a retrospective cohort studyCorticosteroids for the treatment of Kawasaki disease in children.Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)The transcriptional profile of coronary arteritis in Kawasaki diseaseCoronary Diameters in Taiwanese Children Younger than 6 Years Old: Z-Score Regression Equations Derived from Body Surface Area.Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents.Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisitaThe immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.Kawasaki disease in Sicily: clinical description and markers of disease severity.Management of Kawasaki disease.Two cases of super-giant coronary aneurysms after kawasaki diseaseEffect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.Disruption of Endothelial Cell Homeostasis Plays a Key Role in the Early Pathogenesis of Coronary Artery Abnormalities in Kawasaki Disease.Management of acute and refractory Kawasaki disease.An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes.Kawasaki disease: pathophysiology, clinical manifestations, and management.Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.Vasculitides and the Complement System: a Comprehensive Review.A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control StudyKawasaki disease: insights into pathogenesis and approaches to treatment.Kawasaki Disease: Issues in Diagnosis and Treatment--A Developing Country Perspective.Kawasaki disease: a comprehensive review of treatment options.Describing Kawasaki shock syndrome: results from a retrospective study and literature review.
P2860
Q22306356-70F257E1-3C57-4463-9ECE-874EB6228636Q26750499-33C91B48-DFBA-43CC-9EFA-067BBC8134F1Q26777190-EBD94452-5B8B-47D9-8342-14354F430374Q26998791-711C7397-F8C0-4004-87F5-C4AA80A1501AQ28080189-7F3E8C8D-6A0D-4EA1-9B2B-6BA664ED7C94Q29547691-1E5B2480-B87A-4551-9624-9D8C28E5DEF0Q30238784-011787AD-8C71-4202-8D5E-A8761B63E88BQ33419638-FD40F6A5-BC84-44E4-9DB6-8B3C2C1B60A8Q33718985-020DF134-CB11-4FE8-AAD7-446D082E8B3DQ33771697-457F77C9-1173-427C-84E2-A8FB442CC51AQ34836338-67AE9AF9-9E85-4679-9871-26AB2B535CFAQ35063963-41A8A838-1D28-4098-8EC1-FD673160DFA5Q35193974-04F429E1-6A13-4780-AC00-546805413ABFQ35839567-1F1BE444-7003-448C-9F99-10558FE00AB7Q36004589-B1C0A29A-F9F6-4C80-B6DF-790968E6ECBBQ36246685-6E489721-3141-4FB9-8E86-BDA1F5E912AEQ36262749-D9B864F4-D0BD-43BF-894D-5A36CF4509E2Q36374231-625C3C31-91E8-411F-B421-28F0EA52D9AEQ36383442-D56BE2F0-87FE-4D69-B321-F056C3BED046Q36721802-2BB0D5D3-2300-4F63-B75E-2D715B3E753CQ36766177-04126FAB-3245-4B9D-9E83-DC773B70FE76Q37055162-18089DDF-E755-43A8-996F-9B09149866E9Q37175810-13DCD4A2-1161-4E20-BECE-345E2E307D7FQ37364378-2B7FF42D-135F-4217-A86C-56B3828B891DQ37390888-5069C91C-C24B-457D-90B9-8BE09E4EA5A7Q37465500-08941466-954F-4C05-9188-2D71F122BDD5Q37525981-AA955ECB-BFCB-46C1-97DA-616CE5EE3806Q37541457-E27C25B3-1B65-4B21-A83F-0DACF5644554Q37678347-93932A57-2BC5-43F7-94B4-A97274EBE406Q38063969-C66CEA02-2B0A-43A7-A179-790542679FA0Q38104467-CB5BD00B-0CC5-4672-84C5-E4C32341FF93Q38205391-124C0807-34E0-49DD-B787-F667F04A0D9BQ38254482-FBA732FC-0D57-4014-A77C-D3904DA3B70DQ38259908-0B015A78-6970-4011-AA86-8DC92DDE8011Q38322444-8CC60826-57AC-41FC-BC57-AFE7F92136DFQ38374445-6CA04A62-DB0C-44D7-A462-4F1D5AD493CBQ38439648-EA3E8B80-669E-4B0D-91C3-5EB06DE4C134Q38591900-BF02B9CA-5024-429E-BC91-A897DE87553DQ38627718-94403D22-ED1F-475C-9282-50841C10F4F3Q38845448-547BB90B-9C1F-4E09-9122-492CBBFB06B6
P2860
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Efficacy of immunoglobulin plu ...... abel, blinded-endpoints trial.
@en
Efficacy of immunoglobulin plu ...... abel, blinded-endpoints trial.
@nl
type
label
Efficacy of immunoglobulin plu ...... abel, blinded-endpoints trial.
@en
Efficacy of immunoglobulin plu ...... abel, blinded-endpoints trial.
@nl
prefLabel
Efficacy of immunoglobulin plu ...... abel, blinded-endpoints trial.
@en
Efficacy of immunoglobulin plu ...... abel, blinded-endpoints trial.
@nl
P2093
P1433
P1476
Efficacy of immunoglobulin plu ...... abel, blinded-endpoints trial.
@en
P2093
Akihiro Morikawa
Chitose Ogawa
Fukiko Ichida
Hirohide Tokunaga
Hirokazu Arakawa
Kazuo Takeuchi
Kenji Furuno
Kenji Hamaoka
Masaru Miura
Mitsuru Seki
P304
P356
10.1016/S0140-6736(11)61930-2
P407
P577
2012-03-08T00:00:00Z